Patient and Physician Perspectives on Attributes of IO-Containing Perioperative Treatments in Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer (NSCLC)
Author(s)
Matthew Quaife, PhD1, Erica Visintin, PhD1, Gabriela Fernandez, MPH2, Jihyun Park, MSc3, Krassimir Dimitrov, MD4, Rajni Kannan, PhD4, Katrin Dauber, PhD5, Reginald Villacorta, PhD4, Sumeena Bhatia, PhD4, Stefano Lucherini, MSc6.
1Evidera, London, United Kingdom, 2Evidera, Wilmington, NC, USA, 3Bristol Myers Squibb (BMS), Tokyo, Japan, 4Bristol Myers Squibb (BMS), Princeton Pike, Lawrence Township, NJ, USA, 5Bristol Myers Squibb (BMS), München, Germany, 6Bristol Myers Squibb (BMS), Uxbridge, United Kingdom.
1Evidera, London, United Kingdom, 2Evidera, Wilmington, NC, USA, 3Bristol Myers Squibb (BMS), Tokyo, Japan, 4Bristol Myers Squibb (BMS), Princeton Pike, Lawrence Township, NJ, USA, 5Bristol Myers Squibb (BMS), München, Germany, 6Bristol Myers Squibb (BMS), Uxbridge, United Kingdom.
Presentation Documents
OBJECTIVES: The treatment landscape in resectable NSCLC has rapidly evolved with the approval of immunotherapy-based regimens in neoadjuvant and adjuvant settings. Neoadjuvant IO combined with chemotherapy is now the standard of care for eligible patients with resectable NSCLC. This study aimed to understand the perspectives of patients with resectable NSCLC and treating physicians on the benefits and risks of perioperative NSCLC treatments.
METHODS: This non-interventional, cross-sectional study involved the conduct of semi-structured qualitative interviews with 15 resectable NSCLC patients and 40 treating physicians in from Germany, Japan, and the US. Participants ranked efficacy endpoints and undertook a choice task to explore preferences for preventing three-year recurrence, time until surgery, probability of surgery cancellation, and serious side-effects from immunotherapy, chemotherapy and surgery. Qualitative data were analyzed via framework analysis using the RADaR approach.
RESULTS: In the choice task, 73% (n=11) of patients and 92% (n=36) of physicians chose a perioperative regimen over surgery only, and the probability of being recurrence-free after three years was the most important attribute for both patients (60%, n=9) and physicians (75%, n=30). The next most important attributes to patients were time to surgery and serious side-effects from immunotherapy and chemotherapy (each 13%, n=2), whereas for physicians the next most important was probability of surgery cancellation (13%, n=5). Overall survival was the most important endpoint to both patients and physicians (patients: 47%, n=7; physicians: 75%, n=30), followed by pathologic complete response (pCR) (n=5, 33%) for patients and disease-free survival for physicians (n=4, 10%).
CONCLUSIONS: Patient and physician perspectives aligned on the importance of overall survival and preferences for perioperative NSCLC treatments, but patients ranked pCR next-most important, whereas physicians ranked surgery cancellation second. Findings highlight the need for shared decision-making that considers patient and physician priorities to maximize treatment satisfaction and outcomes in resectable NSCLC.
METHODS: This non-interventional, cross-sectional study involved the conduct of semi-structured qualitative interviews with 15 resectable NSCLC patients and 40 treating physicians in from Germany, Japan, and the US. Participants ranked efficacy endpoints and undertook a choice task to explore preferences for preventing three-year recurrence, time until surgery, probability of surgery cancellation, and serious side-effects from immunotherapy, chemotherapy and surgery. Qualitative data were analyzed via framework analysis using the RADaR approach.
RESULTS: In the choice task, 73% (n=11) of patients and 92% (n=36) of physicians chose a perioperative regimen over surgery only, and the probability of being recurrence-free after three years was the most important attribute for both patients (60%, n=9) and physicians (75%, n=30). The next most important attributes to patients were time to surgery and serious side-effects from immunotherapy and chemotherapy (each 13%, n=2), whereas for physicians the next most important was probability of surgery cancellation (13%, n=5). Overall survival was the most important endpoint to both patients and physicians (patients: 47%, n=7; physicians: 75%, n=30), followed by pathologic complete response (pCR) (n=5, 33%) for patients and disease-free survival for physicians (n=4, 10%).
CONCLUSIONS: Patient and physician perspectives aligned on the importance of overall survival and preferences for perioperative NSCLC treatments, but patients ranked pCR next-most important, whereas physicians ranked surgery cancellation second. Findings highlight the need for shared decision-making that considers patient and physician priorities to maximize treatment satisfaction and outcomes in resectable NSCLC.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR137
Topic
Patient-Centered Research
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology